1. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer;Amiri-Kordestani;Clin. Cancer Res.,2014
2. Anon., A study of kadcyla (trastuzumab emtansine) in patients with HER2 positive breast cancer who have received prior anti-HER2 and chemotherapy—based treatment. ClinicalTrials.gov identifier: NCT01702571. 2015a. Available at: www.clinicaltrials.gov last verified: November 2014.
3. Anon., A study of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE). ClinicalTrials.gov identifier: NCT01772472. 2015b. Available at: www.clinicaltrials.gov Last verified: November 2014.
4. Anon., A study of trastuzumab emtansine (T-DM1) sequentially with anthracycline—based chemotherapy, as adjuvant or neoadjuvant therapy for patients with early stage HER2 positive breast cancer. ClinicalTrials.gov identifier: NCT01196052. 2015c. Available at: www.clinicaltrials.gov last verified: September 2014.
5. Anon., A study of kadcyla (trastuzumab emtansine) plus perjeta (pertuzumab) following anthracyclines in comparison with herceptin (trastuzumab) plus perjeta and a taxane following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer. ClinicalTrials.gov identifier: NCT01966471. 2015d. Available at: www.clinicaltrials.gov last verified: November 2014.